Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 18/20 | 0.55 |
| ▸ | BCHE | P06276 | 17/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058855 | 0.96 | PTGS1 (0.62) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2059293 | 0.95 | PTGS1 (0.61) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2059279 | 0.95 | PTGS1 (0.61) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2058902 | 0.92 | PTGS1 (0.67) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2059248 | 0.92 | PTGS1 (0.67) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2058898 | 0.92 | PTGS1 (0.67) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15137470 | 0.90 | PTGS1 (0.64) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL19981067 | 0.89 | PTGS1 (0.60) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15137557 | 0.89 | PTGS1 (0.62) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2059199 | 0.88 | PTGS1 (0.61) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3733642-B1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-10968166-B2 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3733642-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3456707-B1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190270699-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| EP-3456707-A1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BioElectron Technology Corporation (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10167251-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| EP-3018122-B1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECH CORP (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20130289034-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2013-10-31 | — | — | US | disclosed |
| US-8519001-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120122934-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-7968746-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2220030-A2 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | Edison Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009061744-A2 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2009-05-07 | — | — | US | disclosed |
| EP-0604995-B1 | Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena | LIFEGROUP SPA (IT) | 1998-09-30 | — | — | EP | disclosed |
| US-5480645-A | Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena | LIFEGROUP S.P.A. (IT) | 1996-01-02 | — | — | US | disclosed |
| EP-0604995-A1 | Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena | LIFEGROUP S.p.A. (IT) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270699-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2791/4885PTGS2 2540/4885CYP1A2 3891/4885 |
| US-20130289034-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-20120122934-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-10167251-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | PTGS1 2860/4885PTGS2 2651/4885CYP1A2 3880/4885 |
| US-10968166-B2 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | PTGS1 2791/4885PTGS2 2540/4885CYP1A2 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.